Eckert & Ziegler SE (VIE:EUZG)

Austria · Delayed Price · Currency is EUR

15.12

+0.48 (3.28%)

Last updated: Mar 4, 2026, 1:00 PM CET

Market Cap	919.21M
Revenue (ttm)	304.47M
Net Income (ttm)	39.75M
Shares Out	n/a
EPS (ttm)	0.63
PE Ratio	23.12
Forward PE	17.37
Dividend	0.17 (1.09%)
Ex-Dividend Date	Jun 19, 2025

Volume	n/a
Average Volume	315
Open	14.76
Previous Close	14.64
Day's Range	14.67 - 15.13
52-Week Range	14.30 - 23.02
Beta	n/a
RSI	43.08
Earnings Date	Mar 26, 2026

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-co... [Read more]

Industry Industrial Inorganic Chemicals

Founded 1992

Employees 1,112

Stock Exchange Vienna Stock Exchange

Ticker Symbol EUZG

Full Company Profile

Financial Performance

In 2024, Eckert & Ziegler SE's revenue was 295.85 million, an increase of 20.22% compared to the previous year's 246.09 million. Earnings were 33.28 million, an increase of 26.52%.

Financial Statements

News

EQS-AFR: Eckert & Ziegler SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

EQS Preliminary announcement financial reports: Eckert & Ziegler SE / Preliminary announcement on the disclosure of financial statements Eckert & Ziegler SE: Preliminary announcement of the publicatio...

8 days ago - Wallstreet:Online

EQS-AFR: Eckert & Ziegler SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

8 days ago - Wallstreet:Online

Original-Research: Eckert & Ziegler SE (von NuWays AG): BUY • news

27 days ago - Onvista

Eckert & Ziegler SE at JPMorgan Healthcare Conference Transcript

6 weeks ago - GuruFocus

EQS-News: Reorganization of the Eckert & Ziegler Executive Board

EQS-News: Eckert & Ziegler SE / Key word(s): Personnel Reorganization of the Eckert & Ziegler Executive Board 05.12.2025 / 16:10 CET/CEST The issuer is solely responsible for the content of this annou...

3 months ago - Wallstreet:Online

EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Eckert & Ziegler SE Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide di...

3 months ago - Wallstreet:Online

Eckert & Ziegler To Supply SK Biopharmaceuticals With Actinium-225 To Boost Research, Development

SEOUL (dpa-AFX) - Eckert & Ziegler AG (EUZ.F, EUZ.DE), a German isotope technology components firm, said on Wednesday that it has agreed to supply Actinium-225, or Ac-225, to SK Biopharmaceuticals...

3 months ago - Finanz Nachrichten

EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

6 months ago - Wallstreet:Online

EQS-News: Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47%

EQS-News: Eckert & Ziegler SE / Key word(s): Research Update Eckert & Ziegler: Berenberg Starts Coverage with a “Buy” Recommendation and a Price Target of € 24 – Price Potential 47% 09.09.2025 / 11:30...

6 months ago - Wallstreet:Online

Eckert & Ziegler Earnings Surge in Early 2025

Eckert & Ziegler SE, a leader in isotope technology, reports strong financial results for early 2025, signaling continued growth and stability in the radiopharmaceutical sector. Jetzt den vollständige...